Niagen Bioscience, Inc. (NAGE)Consumer Defensive | Packaged Foods | Los Angeles, United States | NasdaqCM
2.58 USD
-0.05
(-1.901%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 8:40 a.m. EDT
The investment case for Niagen Bioscience is currently bifurcated between a speculative gamble on a clinical breakthrough and a fundamental reality check on its financial health. The short-term outlook is aggressively bullish due to heavy call positioning at strikes far above the current price, signaling that traders expect a massive gap-up driven by the upcoming research program rename and Boston fireside chat. However, this optimism ignores a deteriorating operational reality: revenue is contracting by nearly 5%, earnings have collapsed by 75%, and the company is trading at a forward P/E of nearly 27 despite negative earnings growth. While the balance sheet remains intact with minimal debt, the lack of dividend income and the widening gap between the current price ($2.69) and the analyst mean target ($12.08) suggest the market is pricing in a binary 'all-in' scenario rather than a steady recovery. For the long term, the multi-year trajectory shows significant volatility and recent weakness, making the current valuation risky until the new research program proves its commercial viability. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.030961 |
| AutoETS | 0.031212 |
| AutoTheta | 0.037041 |
| AutoARIMA | 0.088766 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 0.27 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.040 |
| Excess Kurtosis | 0.17 |
| Attribute | Value |
|---|---|
| Sector | Consumer Defensive |
| Debt to Equity Ratio | 2.822 |
| Revenue per Share | 1.619 |
| Market Cap | 205,482,368 |
| Trailing P/E | 13.58 |
| Forward P/E | -43.00 |
| Beta | 2.02 |
| Profit Margins | 12.39% |
| Previous Name | ChromaDex Corporation |
| Website | https://www.niagenbioscience.com |
As of Oct. 10, 2026, 8:40 a.m. EDT: Speculators are overwhelmingly bullish on the near term, evidenced by massive open interest in out-of-the-money calls (strikes $5.00 and $7.50) compared to virtually zero put volume or open interest. This indicates a strong expectation of a significant price surge, likely driven by the upcoming catalysts mentioned in news headlines. However, implied volatility is extremely low (under 2%), suggesting the market is pricing in a binary event where the stock either gaps up significantly or remains flat, with little hedging activity against a downside crash.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.64933336 |
| Address1 | 10,900 Wilshire Blvd |
| Address2 | Suite 600 |
| All Time High | 23.66 |
| All Time Low | 0.33 |
| Ask | 3.27 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 650,300 |
| Average Daily Volume3 Month | 568,046 |
| Average Volume | 568,046 |
| Average Volume10Days | 650,300 |
| Beta | 2.017 |
| Bid | 1.9 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 1.044 |
| City | Los Angeles |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.58 |
| Current Ratio | 6.497 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 2.63 |
| Day Low | 2.55 |
| Debt To Equity | 2.822 |
| Display Name | Niagen Bioscience |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,875,400 |
| Earnings Call Timestamp Start | 1,785,875,400 |
| Earnings Growth | -0.75 |
| Earnings Quarterly Growth | -0.733 |
| Earnings Timestamp | 1,785,873,600 |
| Earnings Timestamp End | 1,793,736,000 |
| Earnings Timestamp Start | 1,793,736,000 |
| Ebitda | 9,591,000 |
| Ebitda Margins | 0.0743 |
| Enterprise To Ebitda | 14.63 |
| Enterprise To Revenue | 1.087 |
| Enterprise Value | 140,316,944 |
| Eps Current Year | 0.0 |
| Eps Forward | -0.06 |
| Eps Trailing Twelve Months | 0.19 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.0366 |
| Fifty Day Average Change | -0.4566002 |
| Fifty Day Average Change Percent | -0.15036559 |
| Fifty Two Week Change Percent | -64.933334 |
| Fifty Two Week High | 7.95 |
| Fifty Two Week High Change | -5.37 |
| Fifty Two Week High Change Percent | -0.6754717 |
| Fifty Two Week Low | 2.55 |
| Fifty Two Week Low Change | 0.029999971 |
| Fifty Two Week Low Change Percent | 0.011764695 |
| Fifty Two Week Range | 2.55 - 7.95 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,214,400,600,000 |
| Float Shares | 59,073,286 |
| Forward Eps | -0.06 |
| Forward P E | -43.0 |
| Free Cashflow | 1,641,375 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 117 |
| Fullday Change | -0.05000019 |
| Fullday Change Percent | -1.9011478 |
| Fullday Price | 2.58 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.64239 |
| Gross Profits | 82,922,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.29455 |
| Held Percent Institutions | 0.41527998 |
| Implied Shares Outstanding | 79,644,327 |
| Industry | Packaged Foods |
| Industry Disp | Packaged Foods |
| Industry Key | packaged-foods |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,460,505,600 |
| Last Split Factor | 1:3 |
| Long Business Summary | Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California. |
| Long Name | Niagen Bioscience, Inc. |
| Market | us_market |
| Market Cap | 205,482,368 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_5034211 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-14 |
| Net Income To Common | 15,991,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 238,169,266 |
| Number Of Analyst Opinions | 6 |
| Open | 2.63 |
| Operating Cashflow | 5,949,000 |
| Operating Margins | 0.0235 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Phone | 310 388 6706 |
| Prev Name | ChromaDex Corporation |
| Previous Close | 2.63 |
| Price Hint | 4 |
| Price To Book | 2.4712641 |
| Price To Sales Trailing12 Months | 1.59185 |
| Profit Margins | 0.12388 |
| Quick Ratio | 4.995 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.0500002 |
| Regular Market Change Percent | -1.90115 |
| Regular Market Day High | 2.63 |
| Regular Market Day Low | 2.55 |
| Regular Market Day Range | 2.55 - 2.63 |
| Regular Market Open | 2.63 |
| Regular Market Previous Close | 2.63 |
| Regular Market Price | 2.58 |
| Regular Market Time | 1,791,921,600 |
| Regular Market Volume | 636,467 |
| Return On Assets | 0.05436 |
| Return On Equity | 0.21798 |
| Revenue Growth | -0.043 |
| Revenue Per Share | 1.619 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Consumer Defensive |
| Sector Disp | Consumer Defensive |
| Sector Key | consumer-defensive |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 79,644,327 |
| Shares Percent Shares Out | 0.049000002 |
| Shares Short | 3,874,102 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 4,155,915 |
| Short Name | Niagen Bioscience, Inc. |
| Short Percent Of Float | 0.0754 |
| Short Ratio | 10.1 |
| Source Interval | 15 |
| State | CA |
| Symbol | NAGE |
| Target High Price | 22.0 |
| Target Low Price | 8.5 |
| Target Mean Price | 12.08333 |
| Target Median Price | 10.5 |
| Total Cash | 66,588,000 |
| Total Cash Per Share | 0.84 |
| Total Debt | 2,329,000 |
| Total Revenue | 129,084,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.19 |
| Trailing P E | 13.578947 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.19725 |
| Two Hundred Day Average Change | -1.61725 |
| Two Hundred Day Average Change Percent | -0.3853118 |
| Type Disp | Equity |
| Volume | 636,467 |
| Website | https://www.niagenbioscience.com |
| Zip | 90,024 |